TABLE 4

Participant data at V2 (8 weeks)

ACQ groupFeNO groupp-value#
Subjects n3636
Demographic details
 Mean age years30 (24–46)42 (27–52)0.1
 Height cm172±9173±80.7
 Weight kg71 (62–85)75 (66–80)0.5
 BMI kg·m−224.2 (21.8–26.5)24.3 (21.7–27.7)0.7
 Atopy24 (67)22 (63)0.7
 Smoking0.3
  Current5 (14)11 (28)
  Ex12 (32)10 (25)
  Never20 (54)19 (48)
 Smoking history pack-years6.0 (0.8–11.0)10.0 (5.5–18.8)0.2
Asthma-related QoL
 ACQ1.2 (0.2–1.6)0.8 (0.4–2.0)0.7
 Mini AQLQ6.1 (5.2–6.5)6.3 (5.4–6.7)1.0
Spirometry
 RDR %·mg−10.04 (0.02–0.06)0.03 (0.02–0.06)0.5
 Mean FEV1 L3.25±0.863.25±0.851.0
 Mean FEV1 %92.4±11.394.7±16.20.5
 Mean FVC L4.17±1.184.38±0.890.4
 Mean FEV1/FVC %78.8±8.173.8±9.40.02
FeNO ppb21 (13–32)22 (13–31)1.0
Present treatment
 ICS use37 (97)40 (100)0.3
 ICS dose µg400 (400–400)400 (400–400)0.1
 LABA use6 (15)5 (13)0.8
 LABA dose µg9 (9–18)18 (18–36)0.1
Inflammatory features
 Leukocyte ×109·L−16.5 (5.3–7.8)6.5 (5.3–8.1)0.8
 Eosinophil ×109·L−10.14 (0.11–0.20)0.18 (0.10–0.31)0.5
 Neutrophil ×109·L−14 (2.7–5.2)3.3 (3.1–5.1)0.9
 CRP mg·L−11.1 (0.6–2.5)1.0 (1.0–2.7)0.9
 IgE kU·L−199 (19–325)98 (39–259)1.0
 IL-6 pg·mg−11.2 (0.8–2.1)1.5 (1.0–2.2)0.3
 IL-8 pg·mg−1110 (47–168)116 (80–180)0.6
Sputum inflammation
 Eosinophils %0.38 (0.25–0.82)0.88 (0.25–3)0.1
 Neutrophils %38.0 (21.1–49.1)28.0 (9.1–68.4)0.9
 Macrophages %40.8 (17.3–57)30.6 (18.8–64.3)0.9
 Columnar epithelia %11.4 (4.4–20.6)12.1 (5.0–18.3)0.8

Data are presented as median (interquartile range), mean±sd or n (%), unless otherwise stated. ACQ: Asthma Control Questionnaire; FeNO: exhaled nitric oxide fraction; BMI: body mass index; QoL: quality of life; AQLQ: Asthma Quality of Life Questionnaire; RDR: response dose ratio; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; CRP: C-reactive protein; Ig: immunoglobulin; IL: interleukin. #: based on Chi-squared tests, t-tests and Wilcoxon rank sum tests; : data from 80 subjects (40 in each group).